医学
皮肤病科
安慰剂
不利影响
多中心研究
疾病严重程度
前瞻性队列研究
内科学
随机对照试验
病理
替代医学
作者
Anne Lynn S. Chang,Joanna Badger,Wingfield Rehmus,Alexa B. Kimball
出处
期刊:Journal of Drugs in Dermatology
[SanovaWorks]
日期:2008-04-01
卷期号:7 (4): 379-383
被引量:9
摘要
Introduction Erosive mucosal lichen planus is thought to be an autoimmune disease mediated by increased T-cell activation and proliferation. Alefacept is a biologic agent that selectively targets memory T cells. Objective To evaluate the preliminary efficacy and safety of alefacept in the treatment of moderate to severe mucosal LP. Methods Seven subjects were randomly selected to receive either alefacept 15 mg or placebo every week for 12 weeks. Endpoints of the case series were the Physician Global Assessment (PGA) of disease severity, mucosal pain (MP) severity, and itch severity (IS). Both subjects and investigators were blinded. Results Two of the subjects receiving alefacept achieved significant improvement during the study. There were no serious adverse events during the course of the study period. Conclusions In this small case series, alefacept may have conferred a modest therapeutic response in erosive lichen planus (LP). Larger multicenter prospective studies will be needed to determine whether alefacept can improve erosive LP in a statistically significant way.
科研通智能强力驱动
Strongly Powered by AbleSci AI